ASGCT Policy Summit: Peter Marks on Bespoke Gene and Cell Therapies
Emily Walsh Martin, Ph.D. | September 28, 2020
At the ASGCT Policy Summit, FDA CBER Director Peter Marks, M.D., Ph.D., spoke about the unique challenges in developing gene and cell therapies for very rare diseases.
Policy Summit
Read Full Story